Skip to content
karyopharm-logo Logo for Karyopharm
Main Menu
  • Contact
  • Clinical Trials
  • Careers
  • Follow Us
  • LinkedIn
  • Twitter
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Grants and Giving
    • Careers
      • Our Culture
      • Benefits
      • Job Opportunities
  • Technology & Research
    • Overview
    • Disease Areas of Focus: Hematologic Malignancies & Solid Tumors
      • Multiple Myeloma
      • DLBCL
    • SINE Technology (Selective Inhibitor of Nuclear Export)
    • Supporting Medical Research
    • Publications and Presentations
  • Products
  • Pipeline
    • Overview
    • Oral Selinexor
    • Oral Eltanexor
    • Oral Dual Inhibitor of PAK4 and NAMPT (KPT-9274)
    • Oral Verdinexor
    • Expanded Access
  • Media Center
  • Investors
    • Company Overview
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • SEC Filings
      • Annual Reports & Proxy Statements
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • Analyst Coverage
    • Investor Alerts
    • Press Releases
    • Contact Us
      • Investor FAQs
      • RSS
  • Resources
    • Patient Resources
    • Healthcare Provider Resources

Webinars

Webinar

The Nuclear Pore and XPO1: Guardian of the Genome

September 15, 20201:30pm (EST)  In this webinar, you will hear from Karyopharm’s Founder, President and Chief Scientific Officer and other...

Read More
© Karyopharm, 2020. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Site Map